Regulatory approval
Published by the Health Canada. Approved
VECTIBIX (panitumumab for injection) is indicated as monotherapy for the treatment of patients with non-mutated (wild-type) RAS mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
This is written in the approval document.
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HC (1) | Wild type KRAS, Wild type NRAS | Colorectal Adenocarcinoma | Panitumumab |